Advertisement

Functional food red yeast rice (RYR) for metabolic syndrome amelioration: a review on pros and cons

  • Seema PatelEmail author
REVIEW

Abstract

Red yeast rice (RYR), the fermentation product of mold Monascus purpureus has been an integral part of Oriental food and traditional Chinese medicine, long before the discovery of their medicinal roles. With the identification of bioactive components as polyketide pigments (statins), and unsaturated fatty acids, RYR has gained a nutraceutical status. Hypercholesterolemic effect of this fermented compound has been validated and monacolin K has been recognized as the pivotal component in cholesterol alleviation. Functional similarity with commercial drug lovastatin sans the side effects has catapulted its popularity in other parts of the world as well. Apart from the hypotensive role, ameliorative benefits of RYR as anti-inflammatory, antidiabetic, anticancer and osteogenic agent have emerged, fueling intense research on it. Mechanistic studies have revealed their interaction with functional agents like coenzyme Q10, astaxanthin, vitamin D, folic acid, policosanol, and berberine. On the other hand, concurrence of mycotoxin citrinin and variable content of statin has marred its integration in mainstream medication. In this disputable scenario, evaluation of the scopes and lacunae to overcome seems to contribute to an eminent area of healthcare.

Graphical Abstract

Red yeast rice (RYR), the rice-based fermentation product of mold Monascus purpureus is a functional food. Its bioactive component monacolin K acts like synthetic drug lovastatin, without the severe side effects of the latter. RYR has been validated to lower cholesterol, control high blood pressure; confer anti-flammation, hypoglycaemic, anticancer and osteogenic properties. However, dose inconsistency and co-occurrence of toxin citrinin hampers its dietary supplementation prospect. Further research might facilitate development of RYR as a nutraceutical.

Keywords

Red yeast rice Monascus Monacolin Lovastatin Dyslipidemia 

Notes

Compliance with ethical standards

Conflict of interest

There is no conflict of interest in submission of this manuscript.

References

  1. Abdelbaset M, Safar MM, Mahmoud SS et al (2014) Red yeast rice and coenzyme Q10 as safe alternatives to surmount atorvastatin-induced myopathy in hyperlipidemic rats. Can J Physiol Pharmacol 92:481–489. doi: 10.1139/cjpp-2013-0430 CrossRefGoogle Scholar
  2. Affuso F (2012) A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. World J Cardiol 4:77. doi: 10.4330/wjc.v4.i3.77 CrossRefGoogle Scholar
  3. Aggarwal S, Qamar A, Sharma V, Sharma A (2011) Abdominal aortic aneurysm: a comprehensive review. Exp Clin Cardiol 16:11–15Google Scholar
  4. Atar N, Eren T, Yola ML (2015) A molecular imprinted SPR biosensor for sensitive determination of citrinin in red yeast rice. Food Chem 184:7–11. doi: 10.1016/j.foodchem.2015.03.065 CrossRefGoogle Scholar
  5. Avula B, Cohen PA, Wang Y-H et al (2014) Chemical profiling and quantification of monacolins and citrinin in red yeast rice commercial raw materials and dietary supplements using liquid chromatography-accurate QToF mass spectrometry: chemometrics application. J Pharm Biomed Anal 100:243–253. doi: 10.1016/j.jpba.2014.07.039 CrossRefGoogle Scholar
  6. Balakrishnan B, Karki S, Chiu S-H et al (2013) Genetic localization and in vivo characterization of a Monascus azaphilone pigment biosynthetic gene cluster. Appl Microbiol Biotechnol 97:6337–6345. doi: 10.1007/s00253-013-4745-9 CrossRefGoogle Scholar
  7. Bogsrud MP, Ose L, Langslet G et al (2010) HypoCol (red yeast rice) lowers plasma cholesterol—a randomized placebo controlled study. Scand Cardiovasc J 44:197–200. doi: 10.3109/14017431003624123 CrossRefGoogle Scholar
  8. Brantley SJ, Argikar AA, Lin YS et al (2014) Herb–drug interactions: challenges and opportunities for improved predictions. Drug Metab Dispos 42:301–317. doi: 10.1124/dmd.113.055236 CrossRefGoogle Scholar
  9. Calderon RM, Cubeddu LX, Goldberg RB, Schiff ER (2010) Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc 85:349–356. doi: 10.4065/mcp.2009.0365 CrossRefGoogle Scholar
  10. Chauvin B, Drouot S, Barrail-Tran A, Taburet A-M (2013) Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet 52:815–831. doi: 10.1007/s40262-013-0075-4 CrossRefGoogle Scholar
  11. Chen R-J, Hung C-M, Chen Y-L et al (2012) Monascuspiloin induces apoptosis and autophagic cell death in human prostate cancer cells via the Akt and AMPK signaling pathways. J Agric Food Chem 60:7185–7193. doi: 10.1021/jf3016927 CrossRefGoogle Scholar
  12. Chen G, Shi K, Song D et al (2015a) The pigment characteristics and productivity shifting in high cell density culture of Monascus anka mycelia. BMC Biotechnol 15:72. doi: 10.1186/s12896-015-0183-3 CrossRefGoogle Scholar
  13. Chen H-HS, Neher J, Safranek S (2015b) Clinical inquiry: is red-yeast rice a safe and effective alternative to statins? J Fam Pract 64:128–135Google Scholar
  14. Cheng M-J, Wu M-D, Chen I-S, Yuan G-F (2010) A new sesquiterpene isolated from the extracts of the fungus Monascus pilosus-fermented rice. Nat Prod Res 24:750–758. doi: 10.1080/14786410903178533 CrossRefGoogle Scholar
  15. Childress L, Gay A, Zargar A, Ito MK (2013) Review of red yeast rice content and current Food and Drug Administration oversight. J Clin Lipidol 7:117–122. doi: 10.1016/j.jacl.2012.09.003 CrossRefGoogle Scholar
  16. Chiu H-W, Fang W-H, Chen Y-L et al (2012) Monascuspiloin enhances the radiation sensitivity of human prostate cancer cells by stimulating endoplasmic reticulum stress and inducing autophagy. PLoS ONE 7:e40462. doi: 10.1371/journal.pone.0040462 CrossRefGoogle Scholar
  17. Cho Y-E, Alcantara E, Kumaran S et al (2010) Red yeast rice stimulates osteoblast proliferation and increases alkaline phosphatase activity in MC3T3-E1 cells. Nutr Res 30:501–510. doi: 10.1016/j.nutres.2010.06.011 CrossRefGoogle Scholar
  18. DeBose-Boyd RA (2008) Feedback regulation of cholesterol synthesis: sterol-accelerated ubiquitination and degradation of HMG CoA reductase. Cell Res 18:609–621. doi: 10.1038/cr.2008.61 CrossRefGoogle Scholar
  19. Derosa G, Bonaventura A, Bianchi L et al (2013) A randomized, placebo-controlled study on the effects of a nutraceutical combination of red yeast rice, silybum marianum and octasonol on lipid profile, endothelial and inflammatory parameters. J Biol Regul Homeost Agents 28:317–324Google Scholar
  20. Dill JA, Fuciarelli AF, Lee KM et al (2003) Single administration toxicokinetic studies of decalin (decahydronaphthalene) in rats and mice. Toxicol Sci 72:210–222. doi: 10.1093/toxsci/kfg027 CrossRefGoogle Scholar
  21. Ding M, Si D, Zhang W et al (2014) Red yeast rice repairs kidney damage and reduces inflammatory transcription factors in rat models of hyperlipidemia. Exp Ther Med 8:1737–1744. doi: 10.3892/etm.2014.2035 Google Scholar
  22. Eren T, Atar N, Yola ML, Karimi-Maleh H (2015) A sensitive molecularly imprinted polymer based quartz crystal microbalance nanosensor for selective determination of lovastatin in red yeast rice. Food Chem 185:430–436. doi: 10.1016/j.foodchem.2015.03.153 CrossRefGoogle Scholar
  23. Fasinu PS, Bouic PJ, Rosenkranz B (2012) An overview of the evidence and mechanisms of herb–drug interactions. Front Pharmacol 3:69. doi: 10.3389/fphar.2012.00069 CrossRefGoogle Scholar
  24. Feng Y, Shao Y, Chen F (2012) Monascus pigments. Appl Microbiol Biotechnol 96:1421–1440. doi: 10.1007/s00253-012-4504-3 CrossRefGoogle Scholar
  25. Feuerstein JS, Bjerke WS (2012) Powdered red yeast rice and plant stanols and sterols to lower cholesterol. J Diet Suppl 9:110–115. doi: 10.3109/19390211.2012.682645 CrossRefGoogle Scholar
  26. Finegold JA, Asaria P, Francis DP (2013) Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations. Int J Cardiol 168:934–945. doi: 10.1016/j.ijcard.2012.10.046 CrossRefGoogle Scholar
  27. Fishman JA (2013) Opportunistic infections—coming to the limits of immunosuppression? Cold Spring Harb Perspect Med 3:a015669. doi: 10.1101/cshperspect.a015669 CrossRefGoogle Scholar
  28. Flajs D, Peraica M (2009) Toxicological properties of citrinin. Arch Ind Hyg Toxicol 60:457–464. doi: 10.2478/10004-1254-60-2009-1992 Google Scholar
  29. Fung WT, Subramaniam G, Lee J et al (2012) Assessment of extracts from red yeast rice for herb-drug interaction by in vitro and in vivo assays. Sci Rep 2:298. doi: 10.1038/srep00298 CrossRefGoogle Scholar
  30. Garrido-Maraver J, Cordero MD, Oropesa-Avila M et al (2014) Clinical applications of coenzyme Q10. Front Biosci (Landmark Ed) 19:619–633CrossRefGoogle Scholar
  31. Gerards MC, Terlou RJ, Yu H et al (2015) Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain—a systematic review and meta-analysis. Atherosclerosis 240:415–423. doi: 10.1016/j.atherosclerosis.2015.04.004 CrossRefGoogle Scholar
  32. Gordon RY, Cooperman T, Obermeyer W, Becker DJ (2010) Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med 170:1722–1727. doi: 10.1001/archinternmed.2010.382 Google Scholar
  33. Gurley BJ, Swain A, Williams DK et al (2008) Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John’s wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res 52:772–779. doi: 10.1002/mnfr.200700081 CrossRefGoogle Scholar
  34. Halbert SC, French B, Gordon RY et al (2010) Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 105:198–204. doi: 10.1016/j.amjcard.2009.08.672 CrossRefGoogle Scholar
  35. Hong MY, Seeram NP, Zhang Y, Heber D (2008) Anticancer effects of Chinese red yeast rice versus monacolin K alone on colon cancer cells. J Nutr Biochem 19:448–458. doi: 10.1016/j.jnutbio.2007.05.012 CrossRefGoogle Scholar
  36. Hong MY, Henning S, Moro A et al (2011) Chinese red yeast rice inhibition of prostate tumor growth in SCID mice. Cancer Prev Res (Phila) 4:608–615. doi: 10.1158/1940-6207.CAPR-10-0219 CrossRefGoogle Scholar
  37. Hsieh C-W, Lu Y-R, Lin S-M et al (2013) Stability of monacolin K and citrinin and biochemical characterization of red-koji vinegar during fermentation. J Agric Food Chem 61:7276–7283. doi: 10.1021/jf401542q CrossRefGoogle Scholar
  38. Istvan E (2003) Statin inhibition of HMG-CoA reductase: a 3-dimensional view. Atheroscler Suppl 4:3–8CrossRefGoogle Scholar
  39. James PA, Oparil S, Carter BL et al (2014) 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311:507–520. doi: 10.1001/jama.2013.284427 CrossRefGoogle Scholar
  40. Jernberg E, Thysell E, Bovinder Ylitalo E et al (2013) Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants. PLoS ONE 8:e77407. doi: 10.1371/journal.pone.0077407 CrossRefGoogle Scholar
  41. Jia XQ, Xu ZN, Zhou LP, Sung CK (2010) Elimination of the mycotoxin citrinin production in the industrial important strain Monascus purpureus SM001. Metab Eng 12:1–7. doi: 10.1016/j.ymben.2009.08.003 CrossRefGoogle Scholar
  42. Jirasatid S, Nopharatana M, Kitsubun P, Tongta A (2013) Degradation kinetics of monacolin K in red yeast rice powder using multiresponse modeling approach. J Food Eng 116:436–443. doi: 10.1016/j.jfoodeng.2012.12.018 CrossRefGoogle Scholar
  43. Karl M, Rubenstein M, Rudnick C, Brejda J (2012) A multicenter study of nutraceutical drinks for cholesterol (evaluating effectiveness and tolerability). J Clin Lipidol 6:150–158. doi: 10.1016/j.jacl.2011.09.004 CrossRefGoogle Scholar
  44. Khayznikov M, Hemachrandra K, Pandit R et al (2015) Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by vitamin D supplementation. N Am J Med Sci 7:86–93. doi: 10.4103/1947-2714.153919 CrossRefGoogle Scholar
  45. Klimek M, Wang S, Ogunkanmi A (2009) Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia. P T 34:313–327Google Scholar
  46. Lachenmeier DW, Monakhova YB, Kuballa T et al (2012) NMR evaluation of total statin content and HMG-CoA reductase inhibition in red yeast rice (Monascus spp.) food supplements. Chin Med 7:8. doi: 10.1186/1749-8546-7-8 CrossRefGoogle Scholar
  47. Lam DW, LeRoith D (2012) The worldwide diabetes epidemic. Curr Opin Endocrinol Diabetes Obes 19:93–96. doi: 10.1097/MED.0b013e328350583a CrossRefGoogle Scholar
  48. Lee I-T, Lee W-J, Tsai C-M et al (2012) Combined extractives of red yeast rice, bitter gourd, chlorella, soy protein, and licorice improve total cholesterol, low-density lipoprotein cholesterol, and triglyceride in subjects with metabolic syndrome. Nutr Res 32:85–92. doi: 10.1016/j.nutres.2011.12.011 CrossRefGoogle Scholar
  49. Lee C-I, Shih C-D, Lee C-L et al (2013) Effect of red mold rice on blood coagulation and anticoagulation factors in a rat model of hyperlipidemia. J Funct Foods 5:1956–1965. doi: 10.1016/j.jff.2013.09.017 CrossRefGoogle Scholar
  50. Li Z, Seeram NP, Lee R et al (2005) Plasma clearance of lovastatin versus chinese red yeast rice in healthy volunteers. J Altern Complement Med 11:1031–1038. doi: 10.1089/acm.2005.11.1031 CrossRefGoogle Scholar
  51. Li J-J, Shang X-Y, Li L-L et al (2010) New cytotoxic azaphilones from Monascus purpureus-fermented rice (red yeast rice). Molecules 15:1958–1966. doi: 10.3390/molecules15031958 CrossRefGoogle Scholar
  52. Li P, Yang Y, Liu M (2011) Xuezhikang, extract of red yeast rice, inhibited tissue factor and hypercoagulable state through suppressing nicotinamide adenine dinucleotide phosphate oxidase and extracellular signal-regulated kinase activation. J Cardiovasc Pharmacol 58:307–318. doi: 10.1097/FJC.0b013e3182244a2d CrossRefGoogle Scholar
  53. Li Y, Wu H, Guo L et al (2012) Microsphere-based flow cytometric immunoassay for the determination of citrinin in red yeast rice. Food Chem 134:2540–2545. doi: 10.1016/j.foodchem.2012.04.072 CrossRefGoogle Scholar
  54. Liu J, Zhang J, Shi Y et al (2006) Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med 1:4. doi: 10.1186/1749-8546-1-4 CrossRefGoogle Scholar
  55. Liu Y, Guo X, Duan W et al (2010) Accelerated solvent extraction of monacolin K from red yeast rice and purification by high-speed counter-current chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 878:2881–2885. doi: 10.1016/j.jchromb.2010.08.028 CrossRefGoogle Scholar
  56. Lu L-P, Zhang B-B, Xu G-R (2013) Efficient conversion of high concentration of glycerol to Monacolin K by solid-state fermentation of Monascus purpureus using bagasse as carrier. Bioprocess Biosyst Eng 36:293–299. doi: 10.1007/s00449-012-0784-3 CrossRefGoogle Scholar
  57. Ma J, Li Y, Ye Q et al (2000) Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem 48:5220–5225CrossRefGoogle Scholar
  58. Marazzi G, Cacciotti L, Pelliccia F et al (2011) Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Adv Ther 28:1105–1113. doi: 10.1007/s12325-011-0082-5 CrossRefGoogle Scholar
  59. McCarty MF, O’Keefe JH, DiNicolantonio JJ (2015) Red yeast rice plus berberine: practical strategy for promoting vascular and metabolic health. Altern Ther Health Med 21(Suppl 2):40–45Google Scholar
  60. Moreno PR, Bernardi VH, López-Cuéllar J et al (1996) Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 94:3090–3097CrossRefGoogle Scholar
  61. Moriarty PM, Roth EM, Karns A et al (2014) Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study. J Clin Lipidol 8:568–575. doi: 10.1016/j.jacl.2014.09.002 CrossRefGoogle Scholar
  62. Mornar A, Sertić M, Nigović B (2013) Development of a rapid LC/DAD/FLD/MS n method for the simultaneous determination of monacolins and citrinin in red fermented rice products. J Agric Food Chem 61:1072–1080. doi: 10.1021/jf304881g CrossRefGoogle Scholar
  63. Nigović B, Sertić M, Mornar A (2013) Simultaneous determination of lovastatin and citrinin in red yeast rice supplements by micellar electrokinetic capillary chromatography. Food Chem 138:531–538. doi: 10.1016/j.foodchem.2012.10.104 CrossRefGoogle Scholar
  64. Odegaard JI, Chawla A (2013) The immune system as a sensor of the metabolic state. Immunity 38:644–654. doi: 10.1016/j.immuni.2013.04.001 CrossRefGoogle Scholar
  65. Ogier N, Amiot M-J, Georgé S et al (2013) LDL-cholesterol-lowering effect of a dietary supplement with plant extracts in subjects with moderate hypercholesterolemia. Eur J Nutr 52:547–557. doi: 10.1007/s00394-012-0357-x CrossRefGoogle Scholar
  66. Park H-J, Kim I-S (2011) Antioxidant activities and anticancer effects of red yeast rice grown in the medium containing garlic. Food Sci Biotechnol 20:297–302. doi: 10.1007/s10068-011-0042-5 CrossRefGoogle Scholar
  67. Patakova P (2013) Monascus secondary metabolites: production and biological activity. J Ind Microbiol Biotechnol 40:169–181. doi: 10.1007/s10295-012-1216-8 CrossRefGoogle Scholar
  68. Pirillo A, Catapano AL (2015) Statin intolerance: diagnosis and remedies. Curr Cardiol Rep 17:27. doi: 10.1007/s11886-015-0582-z CrossRefGoogle Scholar
  69. Sanguankeo A, Upala S, Cheungpasitporn W et al (2015) Effects of statins on renal outcome in chronic kidney disease patients: a systematic review and meta-analysis. PLoS ONE 10:e0132970. doi: 10.1371/journal.pone.0132970 CrossRefGoogle Scholar
  70. Sartore G, Giovanni S, Burlina S et al (2013) Mediterranean diet and red yeast rice supplementation for the management of hyperlipidemia in statin-intolerant patients with or without type 2 diabetes. Evid Based Complement Alternat Med 2013:743473. doi: 10.1155/2013/743473 Google Scholar
  71. Seenivasan A, Subhagar S, Aravindan R, Viruthagiri T (2008) Microbial production and biomedical applications of lovastatin. Indian J Pharm Sci 70:701–709. doi: 10.4103/0250-474X.49087 CrossRefGoogle Scholar
  72. Sham T-T, Chan C-O, Wang Y-H et al (2014) A review on the traditional Chinese medicinal herbs and formulae with hypolipidemic effect. Biomed Res Int 2014:925302. doi: 10.1155/2014/925302 CrossRefGoogle Scholar
  73. Shang Q, Liu Z, Chen K et al (2012) A systematic review of xuezhikang, an extract from red yeast rice, for coronary heart disease complicated by dyslipidemia. Evid Based Complement Alternat Med 2012:636547. doi: 10.1155/2012/636547 Google Scholar
  74. Sharma JN, Al-Omran A, Parvathy SS (2007) Role of nitric oxide in inflammatory diseases. Inflammopharmacology 15:252–259. doi: 10.1007/s10787-007-0013-x CrossRefGoogle Scholar
  75. Shi Y-C, Pan T-M (2011) Beneficial effects of Monascus purpureus NTU 568-fermented products: a review. Appl Microbiol Biotechnol 90:1207–1217. doi: 10.1007/s00253-011-3202-x CrossRefGoogle Scholar
  76. Shimizu T, Kinoshita H, Ishihara S et al (2005) Polyketide synthase gene responsible for citrinin biosynthesis in Monascus purpureus. Appl Environ Microbiol 71:3453–3457. doi: 10.1128/AEM.71.7.3453-3457.2005 CrossRefGoogle Scholar
  77. Srivastava RAK, Pinkosky SL, Filippov S et al (2012) AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases: thematic review series: new lipid and lipoprotein targets for the treatment of cardiometabolic diseases. J Lipid Res 53:2490–2514. doi: 10.1194/jlr.R025882 CrossRefGoogle Scholar
  78. Tam EWT, Tsang C-C, Lau SKP, Woo PCY (2015) Polyketides, toxins and pigments in Penicillium marneffei. Toxins (Basel) 7:4421–4436. doi: 10.3390/toxins7114421 CrossRefGoogle Scholar
  79. Thapar M, Russo MW, Bonkovsky HL (2013) Statins and liver injury. Gastroenterol Hepatol (N Y) 9:605–606Google Scholar
  80. Trimarco B, Benvenuti C, Rozza F et al (2011) Clinical evidence of efficacy of red yeast rice and berberine in a large controlled study versus diet. Med J Nutrition Metab 4:133–139. doi: 10.1007/s12349-010-0043-6 CrossRefGoogle Scholar
  81. Trimarco V, Cimmino CS, Santoro M et al (2012) Nutraceuticals for blood pressure control in patients with high-normal or grade 1 hypertension. High Blood Press Cardiovasc Prev 19:117–122. doi: 10.2165/11632160-000000000-00000 Google Scholar
  82. Upchurch GR, Schaub TA (2006) Abdominal aortic aneurysm. Am Fam Physician 73:1198–1204Google Scholar
  83. Venero CV, Venero JV, Wortham DC, Thompson PD (2010) Lipid-lowering efficacy of red yeast rice in a population intolerant to statins. Am J Cardiol 105:664–666. doi: 10.1016/j.amjcard.2009.10.045 CrossRefGoogle Scholar
  84. Verhoeven V, Van der Auwera A, Van Gaal L et al (2015) Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome?: a double blind, placebo controlled randomized trial. BMC Complement Altern Med 15:52. doi: 10.1186/s12906-015-0576-9 CrossRefGoogle Scholar
  85. Wang J, Jiang W, Zhong Y et al (2014) Xuezhikang attenuated the functional and morphological impairment of pancreatic islets in diabetic mice via the inhibition of oxidative stress. J Cardiovasc Pharmacol 63:282–289. doi: 10.1097/FJC.0000000000000047 CrossRefGoogle Scholar
  86. Wang YF, Liu WT, Chen CY et al (2015) Anti-osteoporosis activity of red yeast rice extract on ovariectomy-induced bone loss in rats. Genet Mol Res 14:8137–8146. doi: 10.4238/2015.July.27.2 CrossRefGoogle Scholar
  87. Wei Y, Popovich DG (2013) Red azaphilone pigments extracted from red yeast rice induces cellular senescence and reduces viability in HepG2 cells. Biomed Prev Nutr 3:331–337. doi: 10.1016/j.bionut.2013.08.003 CrossRefGoogle Scholar
  88. Wong RWK, Rabie B (2008) Chinese red yeast rice (Monascus purpureus-fermented rice) promotes bone formation. Chin Med 3:4. doi: 10.1186/1749-8546-3-4 CrossRefGoogle Scholar
  89. Wu M-D, Cheng M-J, Yech Y-J et al (2013) Monascusazaphilones A-C, three new azaphilone analogues isolated from the fungus Monascus purpureus BCRC 38108. Nat Prod Res 27:1145–1152. doi: 10.1080/14786419.2012.715289 CrossRefGoogle Scholar
  90. Xie X, Wang Y, Zhang S et al (2012) Chinese red yeast rice attenuates the development of angiotensin II-induced abdominal aortic aneurysm and atherosclerosis. J Nutr Biochem 23:549–556. doi: 10.1016/j.jnutbio.2011.02.011 CrossRefGoogle Scholar
  91. Xiong X, Wang P, Li X, et al (2015) The effects of red yeast rice dietary supplement on blood pressure, lipid profile and C-reactive protein in hypertension: a systematic review. Crit Rev Food Sci Nutr. doi: 10.1080/10408398.2015.1018987
  92. Yang CW, Mousa SA (2012) The effect of red yeast rice (Monascus purpureus) in dyslipidemia and other disorders. Complement Ther Med 20:466–474. doi: 10.1016/j.ctim.2012.07.004 CrossRefGoogle Scholar
  93. Yang N-C, Chou C-W, Chen C-Y et al (2009) Combined nattokinase with red yeast rice but not nattokinase alone has potent effects on blood lipids in human subjects with hyperlipidemia. Asia Pac J Clin Nutr 18:310–317Google Scholar
  94. Zanardi M, Quirico E, Benvenuti C, Pezzana A (2012) Use of a lipid-lowering food supplement in patients on hormone therapy following breast cancer. Minerva Ginecol 64:431–435Google Scholar
  95. Zhang B-B, Lu L-P, Xu G-R (2015) Why solid-state fermentation is more advantageous over submerged fermentation for converting high concentration of glycerol into Monacolin K by Monascus purpureus 9901: a mechanistic study. J Biotechnol 206:60–65. doi: 10.1016/j.jbiotec.2015.04.011 CrossRefGoogle Scholar
  96. Zhou G, Fu L, Li X (2015) Optimisation of ultrasound-assisted extraction conditions for maximal recovery of active monacolins and removal of toxic citrinin from red yeast rice by a full factorial design coupled with response surface methodology. Food Chem 170:186–192. doi: 10.1016/j.foodchem.2014.08.080 CrossRefGoogle Scholar
  97. Zhu L, Lu J-G, Li T et al (2012a) Immunosuppressive decalin derivatives from red yeast rice. J Nat Prod 75:567–571. doi: 10.1021/np2007236 CrossRefGoogle Scholar
  98. Zhu L, Yau L-F, Lu J-G et al (2012b) Cytotoxic dehydromonacolins from red yeast rice. J Agric Food Chem 60:934–939. doi: 10.1021/jf203579f CrossRefGoogle Scholar
  99. Zhu L, Han Q-B, Ho A et al (2013a) Characterization and simultaneous determination of immunosuppressive decalins in red yeast rice by ultra-high-performance liquid chromatography hyphenated with mass spectrometry. J Chromatogr A 1303:54–61. doi: 10.1016/j.chroma.2013.06.045 CrossRefGoogle Scholar
  100. Zhu X-Y, Li P, Yang Y-B, Liu M-L (2013b) Xuezhikang, extract of red yeast rice, improved abnormal hemorheology, suppressed caveolin-1 and increased eNOS expression in atherosclerotic rats. PLoS ONE 8:e62731. doi: 10.1371/journal.pone.0062731 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2016

Authors and Affiliations

  1. 1.Bioinformatics and Medical Informatics Research CenterSan Diego State UniversitySan DiegoUSA

Personalised recommendations